| 0.1972 0.003 (1.39%) | 06-08 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.27 | 1-year : | 0.32 |
| Resists | First : | 0.23 | Second : | 0.27 |
| Pivot price | 0.2  |
|||
| Supports | First : | 0.16 | Second : | 0.12 |
| MAs | MA(5) : | 0.19  |
MA(20) : | 0.2 |
| MA(100) : | 0.62 |
MA(250) : | 4.02 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 66.2 |
D(3) : | 67.9 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 13.64 | Low : | 0.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABPO ] has closed above bottom band by 32.3%. Bollinger Bands are 92.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 65 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.22 - 0.22 | 0.22 - 0.22 |
| Low: | 0.14 - 0.14 | 0.14 - 0.14 |
| Close: | 0.2 - 0.2 | 0.2 - 0.2 |
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.
Thu, 04 Jun 2026
Abpro Holdings Received Notice of Delisting - TradingView
Wed, 20 May 2026
Abpro Holdings, Inc. 1Q 2026: Revenue $0 Net loss $1.03M, EPS ($0.23) — 10-Q Summary - TradingView
Wed, 20 May 2026
ABPO: Net loss improved to $1.0M, but delisting and legal risks threaten liquidity and operations - TradingView
Fri, 20 Feb 2026
Abpro Holdings to be delisted from Nasdaq after failing equity requirement - Investing.com
Wed, 27 Nov 2024
Abpro (ABP) Stock Price, News & Analysis $ABP - MarketBeat
Fri, 30 Dec 2022
Iqbaljit Kahlon Net Worth (2026) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 16 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | 0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.17 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | 0.25 |
| PEG Ratio | 0 |
| Price to Book value | -0.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|